4 results on '"Clot, Guillem"'
Search Results
2. Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma
- Author
-
Yi, Shuhua, Yan, Yuting, Jin, Meiling, Bhattacharya, Supriyo, Wang, Yi, Wu, Yiming, Yang, Lu, Gine, Eva, Clot, Guillem, Chen, Lu, and Yu, Ying
- Subjects
Gene mutations -- Research ,Leukemia research ,Mantle cell lymphoma -- Genetic aspects -- Development and progression -- Patient outcomes ,Molecular evolution -- Research ,Health care industry - Abstract
Mantle cell lymphoma (MCL) is a phenotypically and genetically heterogeneous malignancy in which the genetic alterations determining clinical indications are not fully understood. Here, we performed a comprehensive whole-exome sequencing analysis of 152 primary samples derived from 134 MCL patients, including longitudinal samples from 16 patients and matched RNA-Seq data from 48 samples. We classified MCL into 4 robust clusters (C1--C4). C1 featured mutated immunoglobulin heavy variable (IGHV), CCND1 mutation, amp(11q13), and active B cell receptor (BCR) signaling. C2 was enriched with del(11q)/ATM mutations and upregulation of NF-[kappa]B and DNA repair pathways. C3 was characterized by mutations in SP140, NOTCH1, and NSD2, with downregulation of BCR signaling and MYC targets. C4 harbored del(17p)/TP53 mutations, del(13q), and del(9p), and active MYC pathway and hyperproliferation signatures. Patients in these 4 clusters had distinct outcomes (5-year overall survival [OS] rates for C1--C4 were 100%, 56.7%, 48.7%, and 14.2%, respectively). We also inferred the temporal order of genetic events and studied clonal evolution of 16 patients before treatment and at progression/relapse. Eleven of these samples showed drastic clonal evolution that was associated with inferior survival, while the other samples showed modest or no evolution. Our study thus identifies genetic subsets that clinically define this malignancy and delineates clonal evolution patterns and their impact on clinical outcomes., Introduction Mantle cell lymphoma (MCL) is an aggressive subtype of non-Hodgkin's B cell lymphoma that has a median overall survival (OS) of approximately 5 years (1-7). MCL can generally be [...]
- Published
- 2022
- Full Text
- View/download PDF
3. Cyclin D1 overexpression induces global transcriptional downregulation in lymphoid neoplasms
- Author
-
Albero, Robert, Enjuanes, Anna, Demajo, Santiago, Castellano, Giancarlo, Pinyol, Magda, Garcia, Noelia, Capdevila, Cristina, Clot, Guillem, Suarez-Cisneros, Helena, Shimada, Mariko, Karube, Kennosuke, Lopez-Guerra, Monica, Colomer, Dolors, Bea, Silvia, Martin-Subero, Jose Ignacio, Campo, Elias, and Jares, Pedro
- Subjects
Cancer genetics -- Research ,Cyclin D -- Physiological aspects -- Health aspects ,Cancer research ,Mantle cell lymphoma -- Genetic aspects ,Transcription (Genetics) -- Health aspects ,Health care industry - Abstract
Cyclin D1 is an oncogene frequently overexpressed in human cancers that has a dual function as cell cycle and transcriptional regulator, although the latter is widely unexplored. Here, we investigated the transcriptional role of cyclin D1 in lymphoid tumor cells with cyclin D1 oncogenic overexpression. Cyclin D1 showed widespread binding to the promoters of most actively transcribed genes, and the promoter occupancy positively correlated with the transcriptional output of targeted genes. Despite this association, the overexpression of cyclin D1 in lymphoid cells led to a global transcriptional downmodulation that was proportional to cyclin D1 levels. This cyclin D1-dependent global transcriptional downregulation was associated with a reduced nascent transcription and an accumulation of promoter-proximal paused RNA polymerase II (Pol II) that colocalized with cyclin D1. Concordantly, cyclin D1 overexpression promoted an increase in the Poll II pausing index. This transcriptional impairment seems to be mediated by the interaction of cyclin D1 with the transcription machinery. In addition, cyclin D1 overexpression sensitized cells to transcription inhibitors, revealing a synthetic lethality interaction that was also observed in primary mantle cell lymphoma cases. This finding of global transcriptional dysregulation expands the known functions of oncogenic cyclin D1 and suggests the therapeutic potential of targeting the transcriptional machinery in cyclin D1-overexpressing tumors., Introduction Cyclin D1 plays a central role in cell cycle regulation, and it is frequently upregulated in cancer by different genomic alterations, including amplifications in breast and respiratory tract tumors [...]
- Published
- 2018
- Full Text
- View/download PDF
4. Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma.
- Author
-
Shuhua Yi, Yuting Yan, Meiling Jin, Bhattacharya, Supriyo, Yi Wang, Yiming Wu, Lu Yang, Gine, Eva, Clot, Guillem, Lu Chen, Ying Yu, Dehui Zou, Jun Wang, An T. Phan, Rui Cui, Fei Li, Qi Sun, Qiongli Zhai, Tingyu Wang, and Zhen Yu
- Subjects
- *
MANTLE cell lymphoma , *B cell receptors , *TRANSCRIPTOMES , *GENETIC mutation , *DNA repair , *CLINICAL indications , *PROTEINS , *SURVIVAL , *RESEARCH , *RESEARCH methodology , *PROGNOSIS , *EVALUATION research , *COMPARATIVE studies , *GENE expression profiling , *GENES , *RESEARCH funding , *NON-Hodgkin's lymphoma - Abstract
Mantle cell lymphoma (MCL) is a phenotypically and genetically heterogeneous malignancy in which the genetic alterations determining clinical indications are not fully understood. Here, we performed a comprehensive whole-exome sequencing analysis of 152 primary samples derived from 134 MCL patients, including longitudinal samples from 16 patients and matched RNA-Seq data from 48 samples. We classified MCL into 4 robust clusters (C1-C4). C1 featured mutated immunoglobulin heavy variable (IGHV), CCND1 mutation, amp(11q13), and active B cell receptor (BCR) signaling. C2 was enriched with del(11q)/ATM mutations and upregulation of NF-κB and DNA repair pathways. C3 was characterized by mutations in SP140, NOTCH1, and NSD2, with downregulation of BCR signaling and MYC targets. C4 harbored del(17p)/TP53 mutations, del(13q), and del(9p), and active MYC pathway and hyperproliferation signatures. Patients in these 4 clusters had distinct outcomes (5-year overall survival [OS] rates for C1-C4 were 100%, 56.7%, 48.7%, and 14.2%, respectively). We also inferred the temporal order of genetic events and studied clonal evolution of 16 patients before treatment and at progression/relapse. Eleven of these samples showed drastic clonal evolution that was associated with inferior survival, while the other samples showed modest or no evolution. Our study thus identifies genetic subsets that clinically define this malignancy and delineates clonal evolution patterns and their impact on clinical outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.